Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim vs short-acting G-CSF for autologous PBSC mobilization in hematologic malignancies
ChiCTR2000035601Phase 4Not yet recruiting
- Sponsor
- Department of Hematology, Affiliated Hospital of Southwest Medical University
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegfilgrastim and filgrastim in hematopoietic malignancies (2 arms), sponsored by Department of Hematology, Affiliated Hospital of Southwest Medical University. Primary endpoints: Peripheral blood hematopoietic stem cells and Peripheral blood mononuclear cells. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
pegfilgrastimfilgrastim
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2000035601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035601.